• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Patient-Reported Outcome Measures in Oncology Drugs Approved by the European Medicines Agency, 2017-2021.2017 - 2021年欧洲药品管理局批准的肿瘤药物的患者报告结局指标
JAMA Netw Open. 2023 Jan 3;6(1):e2251564. doi: 10.1001/jamanetworkopen.2022.51564.
2
A Review of Labeling Based on Patient-Reported Outcome Endpoints for New Oncology Drugs Approved by the European Medicines Agency (2017-2021).基于欧洲药品管理局（2017-2021 年）批准的新型肿瘤药物的患者报告结局终点的标签评价综述。
Value Health. 2023 Jun;26(6):893-901. doi: 10.1016/j.jval.2023.01.017. Epub 2023 Feb 4.
3
A Review of Patient-Reported Outcomes Labeling for Oncology Drugs Approved by the FDA and the EMA (2012-2016).FDA 和 EMA（2012-2016 年）批准的肿瘤药物患者报告结局标签的回顾。
Value Health. 2019 Feb;22(2):203-209. doi: 10.1016/j.jval.2018.09.2842.
4
Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review.评估食品和药物管理局和欧洲药品管理局批准的系统肿瘤治疗药物以及对生活质量有临床意义的改善：系统评价。
JAMA Netw Open. 2021 Feb 1;4(2):e2033004. doi: 10.1001/jamanetworkopen.2020.33004.
5
Post-marketing research and its outcome for novel anticancer agents approved by both the FDA and EMA between 2005 and 2010: A cross-sectional study.2005年至2010年间获美国食品药品监督管理局（FDA）和欧洲药品管理局（EMA）批准的新型抗癌药物的上市后研究及其结果：一项横断面研究。
Int J Cancer. 2018 Jan 15;142(2):414-423. doi: 10.1002/ijc.31061. Epub 2017 Oct 12.
6
Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis.2014-2016 年支持欧洲药品管理局批准癌症药物的随机对照试验的设计特征、偏倚风险和报告：横断面分析。
BMJ. 2019 Sep 18;366:l5221. doi: 10.1136/bmj.l5221.
7
Monitoring evidence on overall survival benefits of anticancer drugs approved by the European Medicines Agency between 2009 and 2015.监测 2009 年至 2015 年间欧洲药品管理局批准的抗癌药物在总生存获益方面的证据。
Eur J Cancer. 2019 Mar;110:1-7. doi: 10.1016/j.ejca.2018.12.026. Epub 2019 Feb 5.
8
Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13.欧洲药品管理局批准的癌症药物对总生存期和生活质量有益的证据可得性：2009 - 2013年药物批准情况的回顾性队列研究
BMJ. 2017 Oct 4;359:j4530. doi: 10.1136/bmj.j4530.
9
Assessing the benefit of cancer drugs approved by the European Medicines Agency using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale over time.随着时间的推移，使用欧洲医学肿瘤学会临床获益程度量表评估欧洲药品管理局批准的癌症药物的获益情况。
Eur J Cancer. 2021 Jun;150:203-210. doi: 10.1016/j.ejca.2021.03.044. Epub 2021 Apr 29.
10
Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019.2010-2019 年美国和欧洲的癌症治疗审批时间、审查速度和关键注册试验的发表情况。
JAMA Netw Open. 2022 Jun 1;5(6):e2216183. doi: 10.1001/jamanetworkopen.2022.16183.

引用本文的文献

1
Acupuncture for cancer-related insomnia: An evidence mapping.针刺治疗癌症相关失眠：一项证据图谱研究。
Integr Med Res. 2025 Dec;14(4):101225. doi: 10.1016/j.imr.2025.101225. Epub 2025 Aug 12.
2
Patient-reported outcomes (PROs) in clinical trials and in clinical practice: report from the XXI national conference of the Italian Association of Medical Oncology (AIOM).临床试验和临床实践中的患者报告结局（PROs）：来自意大利医学肿瘤学会（AIOM）第21届全国会议的报告
BMJ Oncol. 2025 Jun 17;4(1):e000783. doi: 10.1136/bmjonc-2025-000783. eCollection 2025.
3
Clinical Meaningfulness in Alzheimer's Disease Clinical Trials. A Report from the EU-US CTAD Task Force.阿尔茨海默病临床试验中的临床意义。来自欧盟-美国 CTAD 工作组的报告。
J Prev Alzheimers Dis. 2024;11(5):1219-1227. doi: 10.14283/jpad.2024.112.
4
Allies not enemies-creating a more empathetic and uplifting patient experience through technology and art.同盟而非敌人——通过技术与艺术打造更具同理心且令人振奋的患者体验。
Strahlenther Onkol. 2025 Mar;201(3):316-332. doi: 10.1007/s00066-024-02279-7. Epub 2024 Sep 11.
5
Analyses of quality of life in cancer drug trials - a review of measurements and analytical choices in post-reimbursement studies.癌症药物试验中的生活质量分析 - 报销后研究中测量和分析选择的综述。
BMC Cancer. 2024 Mar 6;24(1):311. doi: 10.1186/s12885-024-12045-8.
6
Use of patient-reported outcome measures for oncology drugs receiving accelerated approval.使用患者报告的结局指标评估接受加速审批的肿瘤药物。
Support Care Cancer. 2023 Sep 29;31(10):602. doi: 10.1007/s00520-023-08068-9.
7
The Assessment of Patient-Reported Outcomes for the Authorisation of Medicines in Europe: A Review of European Public Assessment Reports from 2017 to 2022.在欧洲，对药品授权的患者报告结局评估：对 2017 年至 2022 年欧洲公共评估报告的回顾。
Appl Health Econ Health Policy. 2023 Nov;21(6):925-935. doi: 10.1007/s40258-023-00827-3. Epub 2023 Sep 2.

本文引用的文献

1
Incorporating the patient experience into regulatory decision making in the USA, Europe, and Canada.将患者体验纳入美国、欧洲和加拿大的监管决策中。
Lancet Oncol. 2018 May;19(5):e267-e274. doi: 10.1016/S1470-2045(18)30097-4.
2
Patient-reported outcomes: an essential component of oncology drug development and regulatory review.患者报告的结局：肿瘤药物研发与监管审评的重要组成部分。
Lancet Oncol. 2018 May;19(5):595-597. doi: 10.1016/S1470-2045(18)30141-4.

Patient-Reported Outcome Measures in Oncology Drugs Approved by the European Medicines Agency, 2017-2021.

作者信息

Ciani Oriana, Meregaglia Michela, De Lorenzo Francesco, Perrone Francesco, Pinto Carmine

机构信息

Center for Research on Health and Social Care Management, SDA Bocconi, Milan, Italy.

Italian Federation of Oncological Voluntary Associations, Rome, Italy.

出版信息

JAMA Netw Open. 2023 Jan 3;6(1):e2251564. doi: 10.1001/jamanetworkopen.2022.51564.

DOI:10.1001/jamanetworkopen.2022.51564
PMID:36656587
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9857398/
Abstract
摘要